ABBV AbbVie Inc

8-K Current Report

Filed: February 26, 2026

Health Care

Pharmaceutical Preparations

AbbVie Inc (ABBV) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Total debt issuance $8B across 7 tranches, ranging from floating rate to 40-year notes (2066), closing March 4, 2026
• Net proceeds ~$7.95B; $2B earmarked to repay 364-day term loan maturing May 2026, remainder for general corporate/debt purposes

+3 more insights

Other AbbVie Inc 8-K Filings

8-K Mar 4, 2026

Get deeper insights on AbbVie Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.